Advancing End-to-End Continuous Manufacturing for Biologics & Biosimilars 

Time: 1:00 pm
day: Day One Track B AM

Details:

  • CM implementation hurdles when moving from development to phase III manufacturing 
  • Regulatory assessment of CM
  • CoGs is the driver for CM of Biosimilars & Biologics

Speakers: